{"id":"upadacitinib-oral-product","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infections"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK enzymes, upadacitinib reduces the production of pro-inflammatory cytokines and mediators, thereby decreasing inflammation and modulating the immune response. This mechanism of action is thought to contribute to its therapeutic effects in various inflammatory conditions.","oneSentence":"Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:51.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT05843643","phase":"PHASE3","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-07-19","conditions":"Systemic Lupus Erythematosus","enrollment":1000},{"nctId":"NCT05609630","phase":"PHASE3","title":"Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-10-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":90},{"nctId":"NCT04340115","phase":"","title":"Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-04-24","conditions":"Rheumatoid Arthritis (RA)","enrollment":4211},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT03104374","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-01","conditions":"Psoriatic Arthritis","enrollment":642},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06660693","phase":"PHASE3","title":"Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-16","conditions":"Colitis, Ulcerative","enrollment":134},{"nctId":"NCT06227910","phase":"PHASE3","title":"A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-01-02","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT06873100","phase":"PHASE1, PHASE2","title":"Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-11-15","conditions":"Relapsing Polychondritis","enrollment":30},{"nctId":"NCT06758947","phase":"PHASE3","title":"Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-01-15","conditions":"Interstitial Lung Disease Due to Systemic Disease (Disorder)","enrollment":60},{"nctId":"NCT06379958","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Modern Biosciences Ltd","startDate":"2024-04-08","conditions":"Pharmacokinetics","enrollment":48},{"nctId":"NCT06446219","phase":"","title":"Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Upadacitinib Oral Product","genericName":"Upadacitinib Oral Product","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}